Arbiter 6 trial

The ultimate price may be widespread utilization of agents that lack a favorable balance between safety and efficacy. Click here to sign up for a daily email newsletter. Notify me of new posts by email. Enter your email address to subscribe to this blog and receive notifications of new posts by email. Email Address. Sign me up!

CardioBrief One-stop source for cardiology news and links. Home About. Update July 9, : Taylor provided some clarification to CardioBrief. Filed Under: Uncategorized. August 17, at PM. August 27, at PM.

November 15, at PM. Subscribe to Blog via Email Enter your email address to subscribe to this blog and receive notifications of new posts by email. CardioBrief Classics. You Know Nothing, Dr. Researchers also found that the rate of major adverse cardiac events was one percent with niacin Niaspan compared with five percent for ezetimibe Zetia. However, researchers cautioned that the study was not designed to investigate major adverse cardiac events and that the information should only be used as a hypothesis generator.

Furthermore, although the percentage differences appear significant, they actually involved two patients taking niacin and seven patients taking ezetimibe. New England Journal of Medicine Zetia Editorials An editorial published in the New England Journal of Medicine claimed that the trial was ended prematurely and the small sample size should have prevented researchers from concluding that Niaspan is more effective than Zetia. Natural History, Complications and Prognosis.

Medical Therapy. Future or Investigational Therapies. Landmark Trials. List of All Trials. Case 1. Most recent articles. Most cited articles. Review articles. CME Programs. Powerpoint slides. Ongoing Trials at Clinical Trials.